Barriers to commercially viable cell- and tissue therapies

Experts have identified hurdles to the successful commercialisation of innovations in regenerative medicine. Particularly, they recognised challenges in bioreactor-based manufacturing hindering the scale-up of therapies. This field is expensive and risky to invest in so the experts suggest developing manufacturing processes within academia rather than hoping for angel investment.

Manufacturing challenges in regenerative medicine; I. Martin et al; Science Translational Medicine; Vol. 6(232); p. 232; 2014.

http://stm.sciencemag.org/content/6/232/232fs16.full